Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at PLN 329.5B, ahead of Gilead Sciences (PLN 146.4B) and Biogen (PLN 45B). Figures as of 18 Nov 2026, 15:49 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenPLN 329.5B
- Median
- PLN 2.8B
- Combined market value
- PLN 3.37T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | PLN 329.5B | PLN 970.3B | PLN 1,793.86 | 2.59% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | PLN 146.4B | PLN 837.9B | PLN 675.55 | 1.34% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | PLN 45B | PLN 148.1B | PLN 1,001.65 | 0.68% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | PLN 14.8B | PLN 325.2B | PLN 803.81 | 3.35% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | PLN 12.3B | PLN 83.6B | PLN 337.02 | 1.24% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | PLN 10.1B | PLN 41.2B | PLN 199.30 | 0.38% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | PLN 10B | PLN 44.3B | PLN 388.56 | 0.68% up | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | PLN 5.5B | PLN 66B | PLN 652.19 | 2.26% down | 20% up | ||
| 9 | argenxARGX · Health Care | PLN 5.5B | PLN 239.9B | PLN 3,815.26 | 0.13% up | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | PLN 4B | PLN 28B | PLN 26.34 | 4.63% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | PLN 3.4B | PLN 43.8B | PLN 684.88 | 5.01% up | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | PLN 2.9B | PLN 138.4B | PLN 639.78 | 2.21% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | PLN 2.7B | PLN 67.3B | PLN 275.75 | 0.10% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | PLN 1.9B | PLN 45.9B | PLN 292.38 | 0.10% up | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | PLN 1.4B | PLN 16.1B | PLN 165.64 | 2.59% up | 21% down | ||
| 16 | VaxcytePCVX · Health Care | PLN 1.3B | PLN 36.9B | PLN 233.23 | 2.37% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | PLN 1.2B | PLN 18.5B | PLN 114.33 | 0.21% down | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | PLN 780.8M | PLN 25.6B | PLN 390.73 | 0.37% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | PLN 679.2M | PLN 31.1B | PLN 456.52 | 1.36% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | PLN 656.1M | PLN 41.6B | PLN 487.02 | 0.34% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | PLN 638.5M | PLN 22.9B | PLN 187.48 | 3.42% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | PLN 459.4M | PLN 36.5B | PLN 1,231.06 | 2.54% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | PLN 419.9M | PLN 27.9B | PLN 134.72 | 0.87% up | 43% up | ||
| 24 | CG OncologyCGON · Health Care | PLN 156.8M | PLN 28.7B | PLN 321.40 | 1.24% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0215 PLN).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (PLN 329.5B), Gilead Sciences (PLN 146.4B) and Biogen (PLN 45B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 15:49 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of PLN 3.37T as of 18 Nov 2026, 15:49 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.